POLYRIZON LTD
PLRZNASDAQ🏆 #4084 by market capUS Equity
$10.19▼ $1.03 (−10.06%)
🌅 Pre-market$10.20▲ 0.10%Regular close · extended-hours price shown1h—
24h▼ 10.1%
7d▼ 12.3%
14d▼ 11.2%
30d▼ 25.9%
1y▲ 71.2%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
51
Weak
Trading Snapshot
- Day Range
- $10.12 – $10.33
- 52-Week Range
- $2.88 – $18.20
- Volume
- $4.24B
- Avg Volume
- $4.93B
- Shares Outstanding
- 1.1M
- Next Earnings
- Sep 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $534,033
- P/E Ratio
- -2.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.07
- Dividend Yield
- 0.00%
Why Investors Own PLRZ
- ✓High-growth profile — revenue up +27.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▲ +32.3% YoY
Gross Margin (TTM)
62.2%▲ +2.0% YoY
Operating Income (TTM)
$854,956▲ +32.3% YoY
Free Cash Flow (TTM)
$642,964▲ +32.3% YoY
About POLYRIZON LTD
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
51/100
Analyst Price Target
ⓘAverage Target
$12.60
▲ +23.6% Upside
High Target$14.19
Low Target$11.73
Based on 13 analysts
